Equities analysts expect BioTelemetry Inc (NASDAQ:BEAT) to announce $0.42 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for BioTelemetry’s earnings, with the highest EPS estimate coming in at $0.44 and the lowest estimate coming in at $0.38. BioTelemetry posted earnings of $0.32 per share during the same quarter last year, which indicates a positive year over year growth rate of 31.3%. The business is expected to announce its next earnings report on Thursday, February 28th.

According to Zacks, analysts expect that BioTelemetry will report full-year earnings of $1.81 per share for the current year, with EPS estimates ranging from $1.77 to $1.83. For the next year, analysts anticipate that the business will report earnings of $1.78 per share, with EPS estimates ranging from $1.59 to $1.94. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Tuesday, October 30th. The medical research company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.32 by $0.21. BioTelemetry had a net margin of 4.34% and a return on equity of 22.56%. The firm had revenue of $100.00 million for the quarter, compared to analysts’ expectations of $97.89 million. During the same period in the previous year, the firm posted $0.16 EPS. The company’s revenue for the quarter was up 23.5% on a year-over-year basis.

Several equities research analysts have commented on the stock. BidaskClub raised shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 11th. Raymond James cut their price target on shares of BioTelemetry from $66.00 to $64.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 31st. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. BioTelemetry presently has an average rating of “Buy” and an average target price of $61.17.

In other news, SVP Peter Ferola sold 75,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $60.61, for a total value of $4,545,750.00. Following the sale, the senior vice president now directly owns 90,065 shares of the company’s stock, valued at approximately $5,458,839.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert J. Rubin sold 8,489 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $60.36, for a total transaction of $512,396.04. Following the completion of the sale, the director now directly owns 140,040 shares in the company, valued at $8,452,814.40. The disclosure for this sale can be found here. Insiders own 8.30% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Loomis Sayles & Co. L P bought a new stake in shares of BioTelemetry in the 3rd quarter valued at about $23,211,000. Logan Capital Management Inc. lifted its position in shares of BioTelemetry by 5.4% during the third quarter. Logan Capital Management Inc. now owns 52,524 shares of the medical research company’s stock valued at $3,385,000 after purchasing an additional 2,705 shares in the last quarter. Federated Investors Inc. PA lifted its position in shares of BioTelemetry by 8,359.7% during the third quarter. Federated Investors Inc. PA now owns 44,667 shares of the medical research company’s stock valued at $2,879,000 after purchasing an additional 44,139 shares in the last quarter. Castleark Management LLC bought a new position in shares of BioTelemetry during the second quarter valued at about $13,712,000. Finally, Swiss National Bank lifted its position in shares of BioTelemetry by 5.6% during the second quarter. Swiss National Bank now owns 56,600 shares of the medical research company’s stock valued at $2,547,000 after purchasing an additional 3,000 shares in the last quarter. 88.91% of the stock is currently owned by institutional investors.

NASDAQ:BEAT traded down $1.33 on Thursday, hitting $68.16. 573,900 shares of the company’s stock were exchanged, compared to its average volume of 476,633. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.68 and a quick ratio of 2.50. BioTelemetry has a 52 week low of $29.85 and a 52 week high of $74.73. The stock has a market capitalization of $2.25 billion, a PE ratio of 70.27, a price-to-earnings-growth ratio of 3.80 and a beta of 1.75.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Featured Story: Reverse Stock Split

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.